Medicament for suppressing cancer metastasis

Abstract

A cancer metastasis inhibitor which comprises as an active ingredient an anti-tenascin monoclonal antibody which neutralizes the physiological functions of a tenascin by binding to the FGF-like domain and other domains of the tenascin and prevents the metastasis of cancer to other organs such as the lungs.

Claims aren’t available for this document.